Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 5, 2001, Pages 1317-1322

  Pipas, J Marc ^a,b   Mitchell, Sandra E ^a   Barth Jr , Richard J ^a   Vera Gimon, Raul ^a   Rathmann, Joerg ^a   Meyer, Louise P ^a   Wagman, Richard S ^a   Lewis, Lionel D ^a   McDonnell, Carol ^a   Colacchio, Thomas A ^a   Perez, Raymond P ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma of the pancreas; Gemcitabine; Pancreas; Radiotherapy

Indexed keywords

IRRADIATION; PATIENT MONITORING; SURGERY; TOXICITY; TUMORS;

PANCREATIC CANCER;

RADIOTHERAPY;

GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM HEMORRHAGE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RADIATION BEAM; RADIATION DOSE; RADIATION RESPONSE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW DISEASES; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PANCREATECTOMY; PANCREATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, HIGH-ENERGY; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035425404     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01580-2     Document Type: Article

References (24)

1. Cancer statistics, 1999
2. Cancer of the pancreas
3. Neoplasms of the exocrine pancreas
4. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head
5. Combined 5-fluorouracil, and supervoltage radiation therapy of locally unresectable gastrointestinal cancer
6. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluoruracil for locally unresectable pancreatic carcinoma
7. Schedule-dependent antitumor effect of gemcitabine in in vivo model systems
8. Dose scheduling and dosage of gemcitabine
9. Radiosensitization of human tumor cells by gemcitabine in vitro
10. Pancreatic cancer: Adjuvant combined radiation chemotherapy following curative resection
11. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer
12. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation ± 5 FU
13. Preoperative irradiation in carcinoma of the pancreas
14. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas
15. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
16. Radiosensitization of human solid tumor cell lines with gemcitabine
17. Delayed radiosensitization of human colon carcinoma cells after a brief exposure of 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)
18. Radiosensitization produced in vivo by once- versus twice-weekly 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)
19. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
20. A phase 1 study of preoperative gemcitabine (GEM) with radiation therapy (RT) followed by postoperative GEM for patients with localized, resectable pancreatic adenocarcinoma (PaC)
21. A phase 1 study of gemcitabine (GEM) in combination with radiation therapy (RT) in patients with localized, unresectable pancreatic cancer
22. Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity
23. A phase 1 trial of radiation therapy (RT) plus concurrent fixed dose amifostine (AMI) with escalating doses of twice-weekly gemcitabine (TW-GEM) in advanced pancreatic cancer